Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

3198 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-05

Study Completion Date

2018-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The planned trial compares an anthracycline-free taxane based regimen versus a modern third generation (anthracycline/taxane-based) regimen in HER2/neu non-over expressing tumors. The aim is to define a further anthracycline-free standard and to spare anthracycline toxicity to a patient, who will only have a modest benefit from this compound. Prior to randomization for chemotherapy for all patients with HR positive disease OncotypeDX® will be performed to identify patients who should not receive chemotherapy.

Secondary objectives of this trial will be to compare overall survival and toxicity between the two chemotherapy arms, to evaluate survival in the observation arm and to perform translational research regarding prognostic and predictive factors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

NCT00309556

Breast Cancer

COMPLETED PHASE3

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

NCT00620100

Breast Neoplasms

TERMINATED PHASE2

Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel

NCT00527449

Primary Breast Cancer

COMPLETED PHASE2

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255

Breast Neoplasms

COMPLETED PHASE3

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

NCT00461344

Ductal Carcinoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Breast Cancer Her2 Non-overexpressing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Epirubicin and Cyclophosphamid followed by Docetaxel

4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks

Group Type ACTIVE_COMPARATOR

Epirubicin

Intervention Type DRUG

4 cycles, intravenous use, day 1 every three weeks

Cyclophosphamide

Intervention Type DRUG

4 cycles, intravenous infusion, day 1 every three weeks

Docetaxel

Intervention Type DRUG

4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

Combination of Docetaxel and Cyclophosphamid

intravenous infusion on day one every three weeks

Group Type EXPERIMENTAL

Cyclophosphamide

Intervention Type DRUG

6 cycles, intravenous infusion, day 1 every 3 weeks

Docetaxel

Intervention Type DRUG

6 cycles, intravenous infusion, day one every three weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epirubicin

4 cycles, intravenous use, day 1 every three weeks

Intervention Type DRUG

Cyclophosphamide

4 cycles, intravenous infusion, day 1 every three weeks

Intervention Type DRUG

Docetaxel

4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy

Intervention Type DRUG

Cyclophosphamide

6 cycles, intravenous infusion, day 1 every 3 weeks

Intervention Type DRUG

Docetaxel

6 cycles, intravenous infusion, day one every three weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female patients, age at diagnosis 18 - 75 years
* Histological confirmed unilateral primary invasive carcinoma of the breast
* Adequate surgical treatment with complete resection of the tumor (R0) and resection of \> or = 10 axillary nodes or SLN in clinically N0 patients
* T1 - T4 (if operable, inflammatory breast cancer is excluded)
* Her-2 non-over expressing tumor confirmed by IHC/FISH
* Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization
* Node positive disease or node negative disease with at least one other risk factor (tumor size \> or = 2 cm, grade \> or = 2, ER and PR negative, high uPA//PAI-1 levels)
* No evidence for distant metastasis (M0) after conventional staging
* Performance Status ECOG \< or = 1 or KI \> or = 80 %
* The patient must be accessible for treatment and follow-up
* Written informed consent for central pathology review and evaluation of Recurrence Score (HR positive) and participation in the planB trial prior to beginning specific protocol procedures

HR positive patients:

* Patient willingness to participate in adjuvant chemotherapy planB trial if RS \> 11
* Indication for chemotherapy given provided either \> 4 involved lymph nodes or RS \> 11 in 1-3 lymph nodes or N0 disease

* Laboratory requirements (within 21 days prior to randomization):

* Leucocytes \> or = 3.5 109/L
* platelets \> or = 100 109/L
* haemoglobin \> or = 10 g/dL
* total bilirubin \< or = 1 ULN
* ASAT (SGOT) and ALAT (SGPT) \< or = 2.5 UNL
* creatinine \< 175 ymol/L (2 mg/dL)
* Negative pregnancy test (urine or serum) within 7 days prior to randomization in premenopausal patients
* LVEF within normal limits of each institution measured by echocardiography or MUGA scan and

Exclusion Criteria

* HER2 over expression confirmed by IHC/FISH/CISH
* Known hypersensitivity reaction to the compounds or incorporated substances
* Known polyneuropathy \> or = grade 2
* Severe and relevant comorbidity that would interact with the application of cytotoxic agents or the participation in the study including acute cystitis and ischuria and chronic kidney disease.
* Prior malignancy with a disease-free survival of \< 10 years, except curatively treated basalioma of the skin, pTis of the cervix uteri or ipsilateral ductal carcinoma in-situ (DCISpTis of the breast)
* Non-operable breast cancer including inflammatory breast cancer
* Previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor
* Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry
* Male breast cancer
* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less then 1% failure rate) non-hormonal contraceptive measures during the study treatment
* Breast feeding woman
* Sequential breast cancer
* Lack of patient compliance

* Inadequate organ function including:

* Leucocytes \< 3,5 G/l
* platelets \< 100 G/l
* creatinine or bilirubin above normal limits
* alkaline phosphatise \> 5 UNL
* ASAT and/or ALAT associated with AP \> 2.5 UNL
* uncompensated cardiac function
* Time since axillary dissection \> 42 days

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No